A Los Angeles-based firm is making its mark in promoting a product which helps ease pain and reduce the risk of addiction.
Thursday, Endonovo Therapeutics (OTC:ENDV) announced sales of SofPulse units to multiple Plastic Surgery Centers.
SofPulse is Endonovo’s FDA-Cleared, non-invasive device utilized for the reduction of postoperative pain and edema. SofPulse represents a low-cost drug-free solution for reducing opioid usage, accelerating patient recovery and preventing opioid addiction following surgical procedures, with no known side effects and no potential for overdose or dependency.
Endonovo Therapeutics CEO Alan Collier stated, "SofPulse main distribution model is marketing to major hospitals throughout the US and is beginning to be viewed as the standard of care for postoperative pain and edema reduction for numerous inpatient hospital procedures.
"With the expansion of our customer base and recent orders from numerous plastic surgery centers, SofPulse demonstrates different applications for its use."
By noon EST on Thursday, ENDV shares had soared 18 cents, or 8.3%, to $2.34, on 78,000 shares.
